Evofem Biosciences, Inc. (EVFM): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:59 ET
- Event date
- 2026-11-13
- Accession no.
- 0001493152-26-051806
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Evofem reports third-quarter results and provides business update
Evofem reported net sales of $4.6 million for the three months ended September 30, 2026, versus $5.0 million in the prior year period, primarily due to lower PHEXX ex-factory sales. Net income attributable to common stockholders was $0.9 million, compared to a net loss of $1.7 million. The company also disclosed a second manufacturing contract for PHEXX.
- Quarterly net sales were $4.6 million, versus $5.0 million in the prior year period.
- Income from operations was $0.7 million, compared to $1.0 million in the prior year quarter.
- Restricted cash and cash equivalents was $0.3 million as of September 30, 2026.
- Evofem contracted with a second pharmaceutical manufacturer to produce PHEXX.
earnings
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | form8-k.htm |
| EX-99.1 | EX-99.1 | ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.